{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ranibizumab+2.0+mg",
    "query": {
      "intervention": "ranibizumab 2.0 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ranibizumab+2.0+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T18:04:17.588Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01397409",
      "title": "Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "AGN-150998",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Sham Injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 271,
      "start_date": "2011-09-01",
      "completion_date": "2014-04-30",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-09-25T18:04:17.588Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01397409"
    },
    {
      "nct_id": "NCT01469156",
      "title": "Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Polypoidal Choroidal Vasculopathy"
      ],
      "interventions": [
        {
          "name": "ranibizumab 0.5 or 2.0 mg/0.05 cc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southeast Retina Center, Georgia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-09",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2022-12-12",
      "last_synced_at": "2026-09-25T18:04:17.588Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01469156"
    },
    {
      "nct_id": "NCT01334879",
      "title": "High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Radiation Retinopathy"
      ],
      "interventions": [
        {
          "name": "ranibizumab 2.0 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The New York Eye Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2011-05",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2014-10-02",
      "last_synced_at": "2026-09-25T18:04:17.588Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01334879"
    },
    {
      "nct_id": "NCT03345082",
      "title": "A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "OPT-302",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ranibizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sham intravitreal injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Opthea Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 366,
      "start_date": "2017-11-06",
      "completion_date": "2019-05-14",
      "has_results": false,
      "last_update_posted_date": "2021-01-12",
      "last_synced_at": "2026-09-25T18:04:17.588Z",
      "location_count": 55,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Encino, California + 49 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345082"
    },
    {
      "nct_id": "NCT00891735",
      "title": "A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1097,
      "start_date": "2009-07",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2013-01-18",
      "last_synced_at": "2026-09-25T18:04:17.588Z",
      "location_count": 99,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00891735"
    },
    {
      "nct_id": "NCT01225146",
      "title": "Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ischemia",
        "Retinal Vein Occlusion",
        "Pathologic Processes",
        "Retinal Diseases",
        "Eye Diseases"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David M. Brown, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2010-10",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2017-08-14",
      "last_synced_at": "2026-09-25T18:04:17.588Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01225146"
    },
    {
      "nct_id": "NCT01077401",
      "title": "Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 152,
      "start_date": "2010-02",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-09-25T18:04:17.588Z",
      "location_count": 13,
      "location_summary": "Beverly Hills, California • La Jolla, California • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01077401"
    },
    {
      "nct_id": "NCT02457975",
      "title": "Photobiomodulation for the Treatment of Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "670nm PBM",
          "type": "DEVICE"
        },
        {
          "name": "intravitreous VEGF-inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2015-06",
      "completion_date": "2019-08-30",
      "has_results": false,
      "last_update_posted_date": "2019-09-10",
      "last_synced_at": "2026-09-25T18:04:17.588Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02457975"
    },
    {
      "nct_id": "NCT05407636",
      "title": "Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "AMD",
        "nAMD",
        "Wet Age-related Macular Degeneration",
        "wAMD",
        "WetAMD",
        "CNV"
      ],
      "interventions": [
        {
          "name": "ABBV-RGX-314 Dose 1",
          "type": "GENETIC"
        },
        {
          "name": "ABBV-RGX-314 Dose 2",
          "type": "GENETIC"
        },
        {
          "name": "Aflibercept (EYLEA®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "BIOLOGICAL"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 735,
      "start_date": "2022-01-13",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-09-25T18:04:17.588Z",
      "location_count": 107,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05407636"
    },
    {
      "nct_id": "NCT03211234",
      "title": "Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "2.0 mg DE-122 Injectable Solution + Lucentis",
          "type": "DRUG"
        },
        {
          "name": "4.0 mg DE-122 Injectable Solution + Lucentis",
          "type": "DRUG"
        },
        {
          "name": "Lucentis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2017-07-05",
      "completion_date": "2020-01-31",
      "has_results": true,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-09-25T18:04:17.588Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03211234"
    }
  ]
}